Glaxo HPV vaccine shows promise for women 26-55

	Tweet

An experimental cervical cancer vaccine made by GlaxoSmithKline Plc produced immune responses in all women ages 15 to 55 in a clinical study, the first evidence that a cervical cancer vaccine may work in women ages 26 and older, the company said on Monday.

The vaccine, called Cervarix, is designed to prevent infection with the human papilloma virus, or HPV, which causes most cervical cancer.

Researchers in the Phase 3 trial studied 666 women who received Cervarix injections and found 100 percent of them had developed antibodies to the two HPV types the vaccine targets, Glaxo said in a statement. The antibodies were detected seven months after the first of three doses and remained 12 months after the first shot.

Antibody levels were greater or equal to what was seen in females age 15 to 25 in other studies, which have shown 100 percent protection for 4.5 years against the two HPV strains and associated cervical lesions, Glaxo said.

The vaccine was “generally safe and well-tolerated,” Glaxo said.

“These are important data as older women remain at significant risk of acquiring infections with cancer-causing HPV types,” said Dr. Tino Schwarz, a professor at Stiftung Juliusspital Wuerzburg in Germany and the study’s lead author.

The findings were presented at a meeting of the American Society of Clinical Oncology in Atlanta.

Glaxo is lagging rival Merck & Co. Inc. in developing a vaccine for cervical cancer.

Merck is expected to win U.S. approval for its Gardasil experimental vaccine this week based on earlier studies showing it was effective in women and girls ages 9 to 26. Glaxo has said it plans to apply for U.S. approval later this year.

At the same meeting in Atlanta, researchers presented data showing Merck’s Gardasil was 100 percent effective at preventing pre-cancerous growths in the vagina or vulva caused by two HPV strains. It also was 81 percent effective at preventing the same conditions if they were caused by any HPV type, said Dr. Jorma Paavonen, the study’s lead author and chief physician at the University of Helsinki’s obstetrics and gynecology department.

Researchers based the conclusions on data from three clinical trials of more than 18,150 women given either Gardasil or a placebo.

RELATED STORIES:
Cervical cancer vaccine can protect men from HPV   Urinary tract cancer associated with Chinese herbal products containing aristolochic acid   Scientists identify how virus triggers cervical and mouth cancer   Cervical Cancer Rates Higher Among Minority Women   Staging of cervical cancer complicating pregnancy   UK mothers back cervical cancer vaccine for kids   Eight virus types cause almost all cervical cancer   Good results with cervical cancer vaccine in young girls   “Screen and treat” cervical cancer programs effective in poorly resourced areas   Vaccine no replacement for Pap test   Aggressive vaccine effort could cut cervical cancer   New cervical cancer vaccine offers women 100% protection   US FDA approves Hycamtin for cervical cancer   Smoking increases risk cervical cancer   Higher rates of cervical cancer amongst immigrants   Study determines costs of breast and cervical cancer detection among low-income women   Cervical cancer vaccines in development   How Medical Center Research Led to New Cervical Cancer Vaccine   Study indicates vaccine prevents cervical cancer   Merck cervical cancer shot gives 5-year protection   HPV tests better for cervical screening - experts   Optimal Treatment and Minimal Complications in Cervical Cancer Patients

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]